TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00542841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrocortisone withdrawal
Description: This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
Study: NCT03921346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile device app (PedAMINES™) 1st drug
Description: To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile device app (PedAMINES™) 2nd drug
Description: To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile device app (PedAMINES™) 3rd drug
Description: To prepare 4 mL/kg dextrose 10%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile device app (PedAMINES™) 4th drug
Description: To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method 1st drug
Description: To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method 2nd drug
Description: To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method 3rd drug
Description: To prepare 4 mL/kg dextrose 10%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method 4th drug
Description: To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
Study: NCT01918696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anger Reduction Treatment
Description: Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Eight 15-minute sessions of informative videos on healthy living.
Study: NCT00905502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Description: Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
Study: NCT04094337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-assisted treatment
Description: Internet-assisted treatment
Study: NCT03873194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Participants will be instructed to find a comfortable position, with a straight back, feeling the general state of their bodies (tensions, pains, heat, cold, etc.), to relax and pay attention to their own breathing, being aware of the air that gets into and out of the lungs. The women will be told that whenever their attention disperses (to another focus such as a thought, a sound, a body sensation, a judgment, etc.) they should go back to the original focus (breathing) with no feeling/judgment about the loss of focus. The practice involves focus and attention exercises and the gradual insertion of other anchors (focus points) as participants improve their skills in this practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: Early prenatal care, when possible, is recommended as the first measure. Prenatal appointments usually take place fortnightly or weekly for hypertensive pregnant women. Extensive lab testing including specific tests for the first trimester, as well as tests for the diagnosis of superimposed pre-eclampsia and for the evaluation of lesions in target organs.~Drug treatment is only used when non-drug measures against hypertension are inefficient to decrease blood pressure levels and diastolic pressure is 90 mmHg or higher (in the first half of pregnancy) and over 100 mmHg (after 20 weeks).

Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: Early prenatal care, when possible, is recommended as the first measure. Prenatal appointments usually take place fortnightly or weekly for hypertensive pregnant women. Extensive lab testing including specific tests for the first trimester, as well as tests for the diagnosis of superimposed pre-eclampsia and for the evaluation of lesions in target organs.~Drug treatment is only used when non-drug measures against hypertension are inefficient to decrease blood pressure levels and diastolic pressure is 90 mmHg or higher (in the first half of pregnancy) and over 100 mmHg (after 20 weeks).
Study: NCT00462722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg with each exercise session (up to 5 days per week) for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg with each exercise session (up to 5 days per week) for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: with each exercise session (up to 5 days per week) for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: with each exercise session (up to 5 days per week) for 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: with each exercise session (up to 5 days per week) for 9 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musculoskeletal-loading exercise
Description: Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musculoskeletal-loading exercise
Description: Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: musculoskeletal-loading exercise
Description: Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
Study: NCT02536001

Intervention type: DEVICE
Group type: OTHER
Intervention: One mesh Endofast reliant system
Description: One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse

Intervention type: DEVICE
Group type: OTHER
Intervention: two meshes Endofast reliant system
Description: Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
Study: NCT01610154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg QD for 12 weeks
Study: NCT01408758

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Clinician Research Tool (VCRT)
Description: The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).

Intervention type: OTHER
Group type: OTHER
Intervention: No VCRT, only physician counseling at visits
Description: No intervention
Study: NCT01381627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
Study: NCT03075241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoplicone
Description: Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive or inert pill which will be used as a comparator
Study: NCT03054688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnotouch NIBP
Description: Somnotouch NIBP in addition to standard blood pressure measurement
Study: NCT03980184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine 3mg/day Versus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guanfacine
Description: Guanfacine 3mg/day Versus Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Counseling
Description: placebo
Study: NCT02128256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerament G
Study: NCT01342692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: 6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine associated with Valproic acid
Description: 6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.~- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)~- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine associated with Lenalidomide
Description: 6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.~Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine associated with Idarubicine
Description: Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above. Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of Azacitidine or day 10 if azacitidine was administered according to (5-2-2 regimen)
Study: NCT03794258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV+CDI-31244
Description: Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV+CDI-31244+ASV
Description: Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Study: NCT00067990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 100mg
Description: To be started within three months of transplant and continued for five years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No treatment with continued follow-up for five years.
Study: NCT01392716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 375 mg/m2 intravenously once a week for 4 weeks
Study: NCT03604289

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be used as the placebo comparator
Study: NCT04753281

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle counselling
Description: brief psychological intervention, based on the behaviour change whee
Study: NCT00522678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject will receive Placebo matching GW685698X via DISKUS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject will receive Placebo matching GW685698X via DISKUS.
Study: NCT02961881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blinatumomab
Description: Blinatumomab used as both continuous IV infusion and subcutaneous injection
Study: NCT00522678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject will receive Placebo matching GW685698X via DISKUS.
Study: NCT04915456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Steroid (Prednisolone)
Description: Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo additive to topical steroids in a postoperative setting after FESS
Study: NCT02746237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAR5585 Capsules
Description: Single and multiple ascending doses of KAR5585 (100 mg initial dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Single and multiple ascending doses of placebo (100 mg initial dose)
Study: NCT01190449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Given IV
Study: NCT04112355

Intervention type: OTHER
Intervention: Blood Collection
Description: Blood draw

Intervention type: OTHER
Intervention: Blood Collection
Description: Blood draw

Intervention type: OTHER
Intervention: Blood Collection
Description: Blood draw
Study: NCT04562831

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EH301 (Nicotinamide Riboside/Pterostilbene)
Description: Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EH301 (Nicotinamide Riboside/Pterostilbene)
Description: Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.
Study: NCT06632834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin therapy
Description: Simvastatin should be administered initially with the dose of 10 mg once daily for adult and 0.25 mg/Kg once daily for children. Dose of simvastatin will be increased to the dose of 20 mg once daily for adult and 0.5 mg/Kg once daily for children after the check at 3 months without adverse effects.
Study: NCT03658694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rTMS - study 1
Description: Patients will be undergoing to 10Hz transcranial magnetic stimulation session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham rTMS - study 1
Description: Patients will be undergoing to sham transcranial magnetic stimulation session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rTMS - study 2
Description: Patients will be undergoing to 10Hz transcranial magnetic stimulation session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patterned rTMS - stage 2
Description: Patients will be undergoing to theta-burst transcranial magnetic stimulation session
Study: NCT03579680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADT ORDER CHECK ATTESTATION (OR)
Description: Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROVIDER SCRIPT (SC)
Description: The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior.
Study: NCT04414254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)
Description: Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)
Description: Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study.
Study: NCT01414725

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Exercises
Description: Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al \[2009\]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Training
Description: Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation
Description: Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
Study: NCT01503437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine OD Tablets 5 mg
Description: Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine OD Tablets 5 mg
Description: Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
Study: NCT04705883

Intervention type: DRUG
Group type: OTHER
Intervention: Prasterone (DHEA), Micronized
Description: Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
Study: NCT01613183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal Medicine
Description: The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the dummy of a Chinese Medicine prescription
Description: Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
Study: NCT00857168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone MD-Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone MD-Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone MD-Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone MD-Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone MD-Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone MD-Lotion
Study: NCT01677884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
Study: NCT00621907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chirocaine (Levobupivacaine)
Description: levobupivacaine 0,5 % 30 ml infiltration (150 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: sodium chloride : 0,9% 30 ml
Study: NCT02599103

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fat-free milkshake
Description: participants drinks a fat-free milk shakes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: participants drinks the milk shakes prepared from 60g of olive oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean oil
Description: participants drinks the milk shakes prepared from 60g of soybean oil
Study: NCT01677884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)